Magazine Article | January 4, 2022

How Will The CGT Manufacturing Paradigm Mature In 2022?

Source: Life Science Leader

By Anna Rose Welch, Editorial & Community Director, Advancing RNA

Eye-opening. Heterogenous. Challenging. Changeable.

To Robert Hariri, CEO of Celularity; Matthew Durdy, CEO of the Cell and Gene Therapy Catapult; Beth White, CBO & SVP operations of Renovacor; and Geoffrey Glass, CEO of Kiniciti, the past year in the cell and gene therapy (CGT) manufacturing space has been all of these adjectives — and more.

access the Magazine Article!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Life Science Leader

Please tell us more about you so that we can customize our newsletters to your specific interests: